China Sky One Medical, Inc. Obtains Production Rights For Four Drugs

Harbin, China - China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced recently that its subsidiary, Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), successfully obtained production approval from the State Food and Drug Administration (SFDA) in China for four of its newly developed drugs.

-- Dithranol ointment is intended to treat different types of psoriasis, such as plaque psoriasis, guttate psoriasis and hypertrophy psoriasis; -- Antipruritic tincture is intended to soothe itchy skin and reduce inflammation; it can also be used for infection and bruises; -- Antiasthma cream is intended to treat cough, asthma and chronic bronchitis; and -- Levofloxacin Lactate injection is used to treat moderate to severe respiratory system, urinary system, and digestive system infections, as well as soft skin tissue infections. It can also treat septicemia, urethritis, and cervicitis.

"The Chinese government plans to increase subsidies for the rural medical insurance system, which we believe will be a huge potential market for our products," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "These four new drugs address a number of relatively common diseases in rural China and we have already created a sales force aimed at the rural market. We expect to launch these new drugs in the second quarter of 2009 and will provide a detailed sales estimate shortly."

SOURCE: China Sky One Medical, Inc.